Media headlines about TESARO (NASDAQ:TSRO) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TESARO earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.1796178427361 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

Several research firms recently commented on TSRO. Leerink Swann raised TESARO from a “market perform” rating to an “outperform” rating in a research report on Wednesday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $158.00 price objective on shares of TESARO in a research report on Monday, November 20th. Cowen dropped their price objective on TESARO from $125.00 to $80.00 and set a “market perform” rating on the stock in a research report on Tuesday, January 2nd. Piper Jaffray Companies reissued a “hold” rating and issued a $80.00 target price on shares of TESARO in a research report on Tuesday, January 2nd. Finally, Argus set a $154.00 target price on TESARO and gave the stock a “buy” rating in a research report on Tuesday, November 28th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $133.39.

TESARO (NASDAQ TSRO) opened at $68.12 on Friday. The company has a debt-to-equity ratio of 1.75, a current ratio of 4.74 and a quick ratio of 4.35. TESARO has a 12 month low of $52.20 and a 12 month high of $179.77. The company has a market capitalization of $3,788.92, a PE ratio of -7.41 and a beta of 1.40.

TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) EPS for the quarter, missing the consensus estimate of ($2.39) by ($0.96). TESARO had a negative return on equity of 126.44% and a negative net margin of 222.15%. The company had revenue of $48.02 million during the quarter, compared to the consensus estimate of $51.78 million. research analysts expect that TESARO will post -9.54 EPS for the current fiscal year.

In related news, CEO Leon O. Moulder, Jr. acquired 5,000 shares of the firm’s stock in a transaction dated Friday, March 2nd. The shares were purchased at an average price of $56.93 per share, with a total value of $284,650.00. Following the completion of the purchase, the chief executive officer now directly owns 1,018,828 shares of the company’s stock, valued at $58,001,878.04. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Grant C. Bogle sold 1,809 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $54.85, for a total value of $99,223.65. The disclosure for this sale can be found here. In the last ninety days, insiders bought 334,913 shares of company stock worth $19,083,294 and sold 13,042 shares worth $760,526. 40.50% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with's FREE daily email newsletter.